Replies to post #242459 on Biotech Values

[DewDiligence]

ITOS/GSK—TIGIT fallout:

https://finance.yahoo.com/news/iteos-reports-first-quarter-2022-200100680.html

iTeos is working together with GSK to evaluate how best to proceed with additional clinical development of EOS-448 in light of the recent release regarding the Roche SKYSCRAPER-01 study.